Amarillo Biosciences Appoints Bernard Cohen CFO

Amarillo Biosciences Appoints Bernard Cohen CFO

AMARILLO, TX, Sept. 29 /PRNewswire-FirstCall/ - Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that it has appointed Bernard Cohen as Chief Financial Officer (CFO). Mr. Cohen brings over thirty years of management experience to the position. Mr. Cohen replaces Dr. Gary Coy as CFO, who will assist the company with SEC filings as a consultant.

Previously, Mr. Cohen was Director of Finance and Data Base Manager at Harrington Regional Medical Center in Amarillo. Prior, he held various executive positions at Colbert's department store of Amarillo holding the position of CEO, Vice President, Controller, and Personnel Director. Mr. Cohen currently is a member of the Texas Tech University Institutional Review Board, where he reviews clinical trial protocols to monitor the safety and protection of human subjects. Mr. Cohen holds a Masters of Professional Accounting degree (MPA) and a B.A. of Business Administration from West Texas A&M University.

ABI President Joseph Cummins said, "We are delighted to welcome Bernard to our company and look forward to his contribution to financial management. We were fortunate to find someone local with such extensive accounting, IT and executive management background."

"I am extremely pleased to be joining Amarillo Biosciences at a time in which the company has a potential solution to the swine flu pandemic," said Bernard Cohen. "I am confident that my experience in management will enable me to assist the company in attaining its objectives."

    About Amarillo Biosciences

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 7% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including influenza, hepatitis C, chronic cough, and opportunistic infections in patients who are HIV positive. The Company has invested nearly $40 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the web site at

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" and "Item 7A. Qualitative and Quantitative Disclosures About Market Risk" of the Company's Form 10-K for the fiscal year ended December 31, 2008.